Tobin Schilke, CFO at Revance Therapeutics, Inc. (RVNC), sold 13,183 shares at $5.04 ($67K) on 2024-03-18, disclosed to the SEC on 2024-03-19.
Open-market sale of $67k RVNC by CFO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.31 | 3,822 | $20K | 30.1% |
| 2 | $5.04 | 9,361 | $47K | 69.9% |
| Total | $5.12 avg | 13,183 | $67K | 100% |
| Filing → |
| RVNC | SELL | 2023-06-05 | $181K | — | Filing → |
| RVNC | SELL | 2023-05-16 | $1.5M | — | Filing → |
| RVNC | SELL | 2023-05-02 | $203K | — | Filing → |